

CITATION REPORT

List of articles citing

Suboptimal aminoglycoside dosing in critically ill patients

DOI: 10.1097/ftd.ob013e31818b6b2f
Therapeutic Drug Monitoring, 2008, 30, 674-81.

Source: <https://exaly.com/paper-pdf/45010160/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
116	Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter?. 2009 , 13, 214		127
115	Pharmacokinetics and pharmacodynamics in critically ill patients. 2010 , 23, 472-8		37
114	Once-daily gentamicin dosing in children with febrile neutropenia resulting from antineoplastic therapy. <i>Pharmacotherapy</i> , 2010 , 30, 43-51	5.8	10
113	Pharmacokinetics of gentamicin in critically ill patients: pilot study evaluating the first dose. 2010 , 16, 1258-63		31
112	Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation. 2010 , 70, 201-12		71
111	Amikacin monotherapy for sepsis caused by panresistant <i>Pseudomonas aeruginosa</i> . 2010 , 54, 4939-41		40
110	Continuing education: alternative approaches to optimizing antimicrobial pharmacodynamics in critically ill patients. 2010 , 23, 6-18		5
109	Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clinical Pharmacokinetics</i> , 2010 , 49, 1-16	6.2	245
108	Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. 2010 , 14, R53		139
107	An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients. 2010 , 16, 333-43		48
106	Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy. <i>International Journal of Antimicrobial Agents</i> , 2011 , 37, 531-5	14.3	47
105	Can Pharmacokinetic and Pharmacodynamic Principles Be Applied to the Treatment of Multidrug-Resistant <i>Acinetobacter</i> ?. 2011 , 45, 229-40		9
104	Pharmacological considerations for the proper clinical use of aminoglycosides. 2011 , 71, 2277-94		71
103	Clinical experience with aminoglycosides in dialysis-dependent patients: risk factors for mortality and reassessment of current dosing practices. 2011 , 45, 1338-45		10
102	Rationality of Administered Gentamicin Dose in Cerebral Coma Patients Treated in an Intensive Care Unit. 2011 , 47, 10		
101	Antibiotic dosing during sustained low-efficiency dialysis: special considerations in adult critically ill patients. 2011 , 39, 560-70		67
100	Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations. 2011 , 71, 61-71		31

99	Appropriate antibiotic dosage levels in the treatment of severe sepsis and septic shock. 2011 , 13, 406-15	23
98	Early and adequate antibiotic therapy in the treatment of severe sepsis and septic shock. 2011 , 13, 399-405	23
97	Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration. 2011 , 55, 4639-42	23
96	Outcomes in patients with gram-negative sepsis treated with gentamicin. 2012 , 3, 109-13	2
95	Guidelines for the Monitoring of Vancomycin, Aminoglycosides and Certain Antibiotics. 2012 , 197-218	5
94	Management of antimicrobial use in the intensive care unit. 2012 , 72, 447-70	14
93	Importance of High Creatinine Clearance for Antibacterial Treatment in Sepsis. 2012 , 171-197	
92	Therapeutic drug monitoring of antimicrobials. 2012 , 73, 27-36	197
91	Dose modulation: a new concept of antibiotic therapy in the critically ill patient?. 2013 , 28, 341-6	16
90	Evaluating amikacin dosage regimens in intensive care unit patients: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation. <i>International Journal of Antimicrobial Agents</i> , 2013 , 42, 155-60	14.3 13
89	Timing of appropriate antibiotics in patients with septic shock: a retrospective cohort study. 2013 , 25, 308-15	16
88	Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk. 2013 , 36, 217-30	43
87	Therapeutic drug monitoring of amikacin in septic patients. 2013 , 17, R165	54
86	[Calculation of the first dose of amikacin: evaluation of the current dosage recommendations]. 2013 , 71, 7-12	1
85	Treatment of carbapenem-resistant <i>Klebsiella pneumoniae</i> : the state of the art. 2013 , 11, 159-77	104
84	Carbapenem resistance in <i>Acinetobacter baumannii</i> : laboratory challenges, mechanistic insights and therapeutic strategies. 2013 , 11, 395-409	91
83	Objectifs pharmacocinétiques, pharmacodynamiques (PK/PD) et adaptation posologique des antibiotiques chez le patient de réanimation : vers une approche pratique. 2013 , 83-103	
82	Aminoglycoside use in critically ill patients requires careful regimen planning and drug monitoring to avoid nephrotoxicity. 2013 , 29, 282-286	

81	Optimal dosing of antibiotics in critically ill patients by using continuous/extended infusions: a systematic review and meta-analysis. 2013 , 17, R279		39
80	Methods to Measure Target Site Penetration of Antibiotics in Critically Ill Patients. 2013 , 8, 46-58		
79	Effect of age on the pharmacokinetics of a single daily dose of gentamicin sulfate in healthy foals. 2013 , 45, 507-11		15
78	Plasma Pharmacokinetics of Antimicrobial Agents in Critically Ill Patients. 2013 , 8, 5-12		1
77	Methods to Measure Target Site Penetration of Antibiotics in Critically Ill Patients. 2013 , 8, 46-58		1
76	Predictive performance of gentamicin dosing nomograms. <i>Drug Design, Development and Therapy</i> , 2014 , 8, 1097-106	4.4	2
75	How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?. 2014 , 14, 288		67
74	Toxicidad antibacterianos: farmacocinética-farmacodinamia: prevención y manejo. 2014 , 25, 445-456		0
73	Propensity-based study of aminoglycoside nephrotoxicity in patients with severe sepsis or septic shock. 2014 , 58, 7468-74		34
72	Dose derivation of once-daily dosing guidelines for gentamicin in critically ill pediatric patients. <i>Therapeutic Drug Monitoring</i> , 2014 , 36, 288-94	3.2	8
71	How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it?. 2014 , 79, 441-7		45
70	Stratégies de réduction de l'utilisation des antibiotiques visées curative en réanimation (adulte et pédiatrique). 2014 , 23, 558-582		3
69	Is the standard dose of amoxicillin-clavulanic acid sufficient?. 2014 , 15, 38		13
68	Oxygen delivery, cardiac function and monitoring. 1-12		
67	Optimizing antimicrobial therapy in the ICU. 173-186		
66	Plasma Peak and Trough Gentamicin Concentrations in Hospitalized Horses Receiving Intravenously Administered Gentamicin. 2015 , 29, 1660-6		15
65	Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearance. 2015 , 17, 493		37
64	Antibiotic dose optimization in critically ill patients. 2015 , 39, 563-572		1

63	First-dose pharmacokinetics of aminoglycosides in critically ill haematological malignancy patients. <i>International Journal of Antimicrobial Agents</i> , 2015 , 45, 46-53	14.3	14
62	Once-daily aminoglycoside dosing: An update on current literature. 2015 , 72, 1357-64		40
61	Stratégies de réduction de l'utilisation des antibiotiques visées curative en réanimation (adulte et pédiatrique). 2015 , 1, 373-396		3
60	Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations. <i>International Journal of Antimicrobial Agents</i> , 2015 , 46, 21-7	14.3	48
59	Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development. 2015 , 36, 136-53		93
58	Antibiotic dose optimization in critically ill patients. 2015 , 39, 563-72		27
57	Pharmacodynamic Considerations in Critically Ill Patients. 2016 , 537-560		1
56	Therapeutic drug monitoring of anti-infective agents in critically ill patients. 2016 , 9, 961-79		77
55	Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing. 2016 , 38, 1930-47		73
54	Assessment of the National French recommendations regarding the dosing regimen of 8mg/kg of gentamicin in patients hospitalised in intensive care units. 2016 , 35, 331-335		10
53	Comment on: Mortality due to blaKPC Klebsiella pneumoniae bacteraemia. 2016 , 71, 1743-4		5
52	A high-dose aminoglycoside regimen combined with renal replacement therapy for the treatment of MDR pathogens: a proof-of-concept study. 2016 , 71, 1386-94		20
51	Successful treatment of a Carbapenem-resistant Klebsiella pneumoniae carrying bla OXA-48 , bla VIM-2 , bla CMY-2 and bla SHV- with high dose combination of imipenem and amikacin. 2016 , 4, 10-2		10
50	Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. 2017 , 43, 304-377		3178
49	Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis. 2017 , 61,		35
48	Population pharmacokinetic modelling, Monte Carlo simulation and semi-mechanistic pharmacodynamic modelling as tools to personalize gentamicin therapy. 2017 , 72, 639-667		20
47	Population Pharmacokinetic Characteristics of Amikacin in Suspected Cases of Neonatal Sepsis in a Low-Resource African Setting: A Prospective Nonrandomized Single-Site Study. 2017 , 84, e1-e6		4
46	Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. 2017 , 45, 486-552		1683

45	Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility. 2017 , 15, 519-526		37
44	Determinants of gentamicin concentrations in critically ill patients: a population pharmacokinetic analysis. <i>International Journal of Antimicrobial Agents</i> , 2017 , 49, 204-211	14.3	23
43	The challenge of curbing aminoglycoside resistance: can antimicrobial stewardship programs play a critical role?. 2017 , 15, 947-954		5
42	Therapeutic Drug Monitoring of Gentamicin Peak Concentrations in Critically Ill Patients. <i>Therapeutic Drug Monitoring</i> , 2017 , 39, 522-530	3.2	16
41	Therapeutic Drug Monitoring of Beta-Lactams and Other Antibiotics in the Intensive Care Unit: Which Agents, Which Patients and Which Infections?. 2018 , 78, 439-451		63
40	Determinants of amikacin first peak concentration in critically ill patients. 2018 , 32, 669-677		5
39	Predictive performance of a gentamicin population pharmacokinetic model in two western populations of critically ill patients. <i>International Journal of Antimicrobial Agents</i> , 2018 , 52, 218-225	14.3	6
38	Appropriate Antimicrobial Therapy in Critically Ill Patients. 2018 , 319-342		
37	Emergence of polymyxin B resistance in a polymyxin B-susceptible KPC-producing <i>Klebsiella pneumoniae</i> causing bloodstream infection in a neutropenic patient during polymyxin B therapy. 2018 , 90, 134-138		11
36	Antibiotic Pharmacokinetic/Pharmacodynamic Considerations in the Critically Ill. 2018 ,		2
35	Augmented Renal Clearance. 2018 , 125-150		3
34	New paradigm for rapid achievement of appropriate therapy in special populations: coupling antibiotic dose optimization rapid microbiological methods. 2018 , 14, 693-708		8
33	What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 1407-1443	6.2	47
32	Pharmacokinetics and Pharmacodynamics of Antibiotics in Transplant Patients. 2019 , 903-925		
31	Rules of anti-infection therapy for sepsis and septic shock. 2019 , 132, 589-596		13
30	Improving peak concentrations of a single dose regime of gentamicin in patients with sepsis in the emergency department. <i>PLoS ONE</i> , 2019 , 14, e0210012	3.7	3
29	What Are the Current Approaches to Optimising Antimicrobial Dosing in the Intensive Care Unit?. <i>Pharmaceutics</i> , 2020 , 12,	6.4	16
28	Aminoglycoside Dosing and Volume of Distribution in Critically Ill Surgery Patients. 2020 , 21, 859-864		2

27	External Validation of Model-Based Dosing Guidelines for Vancomycin, Gentamicin, and Tobramycin in Critically Ill Neonates and Children: A Pragmatic Two-Center Study. 2020 , 22, 433-444		6
26	[S3 Guideline Sepsis-prevention, diagnosis, therapy, and aftercare : Long version]. 2020 , 115, 37-109		15
25	Renal safety of a single dose of gentamicin in patients with sepsis in the emergency department. 2020 ,		3
24	Use of aminoglycoside antibiotics in equine clinical practice; a questionnaire-based study of current use. 2021 , 7, 279-288		1
23	Population pharmacokinetic modeling and clinical application of vancomycin in Chinese patients hospitalized in intensive care units. 2021 , 11, 2670		2
22	An international survey on aminoglycoside practices in critically ill patients: the AMINO III study. 2021 , 11, 49		5
21	Aminoglycosides in the Intensive Care Unit: What Is New in Population PK Modeling?. <i>Antibiotics</i> , 2021 , 10,	4.9	2
20	The Synergistic Activity and Optimizing Doses of Tigecycline in Combination with Aminoglycosides against Clinical Carbapenem-Resistant Isolates. <i>Antibiotics</i> , 2021 , 10,	4.9	1
19	Pharmacokinetic/pharmacodynamic evaluation of tobramycin dosing in critically ill patients: the Hartford nomogram does not fit. 2021 , 76, 2335-2341		1
18	Aminoglycosides in Critically Ill Septic Patients With Acute Kidney Injury Receiving Continuous Renal Replacement Therapy: A Multicenter, Observational Study. 2021 , 43, 1116-1124		0
17	Optimizing Antimicrobial Drug Dosing in Critically Ill Patients. 2021 , 9,		8
16	Quantification and Explanation of the Variability of First-Dose Amikacin Concentrations in Critically Ill Patients Admitted to the Emergency Department: A Population Pharmacokinetic Analysis. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021 , 46, 653-663	2.7	1
15	Aminoglycosides and aminocyclitols. 2011 , 145-169		7
14	Therapeutic Drugs and Their Management. 2012 , 1057-1108		2
13	Correlations between Income inequality and antimicrobial resistance. <i>PLoS ONE</i> , 2013 , 8, e73115	3.7	12
12	Calculated initial parenteral treatment of bacterial infections: Pharmacokinetics and pharmacodynamics. <i>GMS Infectious Diseases</i> , 2020 , 8, Doc17	0.9	3
11	Open-source maximum a posteriori-bayesian dosing AdDS to current therapeutic drug monitoring: Adapting to the era of individualized therapy. <i>Pharmacotherapy</i> , 2021 , 41, 953-963	5.8	0
10	Aminoglycosides. 2011 , 938-942		

9	Population Pharmacokinetics and Dosing Optimization of Gentamicin in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.. <i>Drug Design, Development and Therapy</i> , 2022 , 16, 13-22	4.4	1
8	Risk Factors Associated with Suboptimal Tobramycin Levels in the Medical Intensive Care Unit.. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2022 , 47, 271	2.7	
7	The Role of Surface Enhanced Raman Scattering for Therapeutic Drug Monitoring of Antimicrobial Agents. <i>Chemosensors</i> , 2022 , 10, 128	4	0
6	Antimicrobial Activity Profiles and Potential Antimicrobial Regimens against Carbapenem-Resistant Enterobacterales Isolated from Multi-Centers in Western Thailand.. <i>Antibiotics</i> , 2022 , 11,	4.9	1
5	PK/PD guided gentamicin dosing in critically ill patients: a revisit of the Hartford nomogram.. <i>International Journal of Antimicrobial Agents</i> , 2022 , 106600	14.3	0
4	Clinical Pharmacokinetics of Gentamicin in Various Patient Populations and Consequences for Optimal Dosing for Gram-Negative Infections: An Updated Review. <i>Clinical Pharmacokinetics</i> ,	6.2	1
3	Model Re-Estimation: An Alternative for Poor Predictive Performance during External Evaluations? Example of Gentamicin in Critically Ill Patients. <i>Pharmaceutics</i> , 2022 , 14, 1426	6.4	0
2	Optimization of Pediatric Antibiotic Dosing Through Therapeutic Drug Monitoring.		0
1	Population Pharmacokinetics and AUC-Guided Dosing of Tobramycin in the Treatment of Infections Caused by Glucose-Nonfermenting Gram-Negative Bacteria. 2023 ,		0